About Lipid Therapeutics
Lipid Therapeutics GmbH was founded in early 2008 in Heidelberg. The mission is to develop novel therapies for inflammatory diseases of the digestive system. The company's current focus is to develop LT-02, a retard formulation of phosphatidylcholine, for the treatment of Ulcerative Colitis based on the preclinical and clinical work conducted by Prof. Stremmel from the University Hospital Heidelberg.
© 2013 BioRN Cluster Management GmbH • All Rights Reserved • Contact & Legal Notice